Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Single-Arm Trial of Epratuzumab, an Anti-CD22 Humanized Antibody, in Patients With Waldenstrom's Macroglobulinemia

NCT00113802 is registered in ClinicalTrials.gov with Gilead Sciences as lead sponsor.

NCT NCT00113802
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00113802 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Single-Arm Trial of Epratuzumab, an Anti-CD22 Humanized Antibody, in Patients With Waldenstrom's Macroglobulinemia
Lead sponsor
Gilead Sciences
Phase
Phase 2
Overall status
Terminated
Start date
August 31, 2004
Completion date
December 31, 2006
Enrollment
31
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

waldenstrom macroglobulinemia